[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.
Dimai
Hans Peter
HP
Klinische Abteilung für Endokrinologie und Nuklearmedizin, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria. hans.dimai@meduni-graz.at
Pietschmann
Peter
P
Resch
Heinrich
H
Preisinger
Elisabeth
E
Fahrleitner-Pammer
Astrid
A
Dobnig
Harald
H
Klaushofer
Klaus
K
D001317:Austria; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016103:Spinal Fractures / Q000517:prevention & control
D050071:Bone Density Conservation Agents